Articles related to REAL-WORLD EVIDENCE

A randomized noninferiority trial found that oral fosfomycin matched continued intravenous therapy in stabilized patients with ESBL complicated UTIs after 3 to 7 days of initial IV treatment.

Among nearly 450,000 Scottish adults with hypertension, participants using a digital home blood pressure telemonitoring system showed lower rates of cardiovascular events, hospitalizations, and death compared with those receiving standard care over a median observation period spanning 2019 to 2022.

In a retrospective VA cohort of 669 mCRPC patients who did not progress on initial docetaxel, rechallenge with docetaxel was associated with improved overall survival compared with cabazitaxel after inverse probability of treatment weighting, though short follow-up and inherent selection pressures limit interpretation.

GLP-1 receptor agonist use was associated with a 41% lower overall risk of obesity-related cancers in a retrospective cohort of more than 229,000 non-diabetic patients with obesity, with the largest risk reductions observed in endometrial, pancreatic, colorectal, and multiple myeloma.

A retrospective analysis of more than 840,000 patients with breast cancer found lower all-cause mortality and reduced recurrence risk among those with obesity or type 2 diabetes who received GLP-1 receptor agonists compared with similar patients who did not, though the study did not establish causation.

A retrospective cohort study of 349,168 propensity-matched patients with diabetes found a hazard ratio of 2.22 for nonarteritic anterior ischemic optic neuropathy among semaglutide users compared with non-GLP-1 RA antidiabetic therapy users, with elevated risk emerging at two years and persisting through four years of follow-up.